Brooks Laboratories EBITDA TCAC 5A

Que fait Brooks Laboratories ? Brooks Laboratories Ltd. manufactures pharmaceutical products including Carbapenem category drugs such as Imipenem 250mg + Cilastatin 250mg, Meropenem 125mg, and Doripenem 500mg. The company produces Penicillins in injections, tablets, and dry syrup forms, along with General category products like liquid injections, dry powder injections, and eye/ear drops. Brooks Laboratories markets its pharmaceuticals nationally and internationally to regulated markets through its manufacturing plants in Baddi, Himachal Pradesh. The firm generates revenue by selling these dosage forms to healthcare providers and distributors in regulated pharmaceutical markets. The company's product portfolio includes specific formulations like Iron sucrose 100mg/5ml liquid injections under the General category. Brooks Laboratories targets regulated markets globally for its Carbapenem, Penicillin, and General category products. Its manufacturing operations at Baddi enable nationwide and international distribution of pharmaceuticals. Revenue is derived from the sale of these branded and generic pharmaceutical products to hospitals, pharmacies, and international buyers in compliant markets. Brooks Laboratories focuses on producing injectable and oral dosage forms including tablets, dry syrup, and eye/ear drops. The company's Carbapenem category features Meropenem 1000mg+Tazobactam 500mg and Doripenem 1000mg. Penicillins are available as injections, tablets, and dry syrup. The firm's revenue model relies on direct sales of these pharmaceutical products to healthcare institutions and distributors in regulated markets, ensuring compliance with international pharmaceutical standards. Brooks Laboratories est l'une des entreprises les plus populaires sur Eulerpool.